By: Daniel Trecroci
On January 13, 2004, Abbott Laboratories bought TheraSense, Inc. for $1.2 billion.
The acquisition, expected to close in the second quarter, expands Abbott’s presence in the diabetes market. In addition to its line of MediSense meters, Abbott will now pick up TheraSense’s FreeStyle meter, as well as TheraSense’s FreeStyle Navigator continuous blood glucose monitor.
TheraSense and Deltec plan to launch the CozMore Insulin Technology System, which combines TheraSens’s blood glucose testing technology and insulin delivery options in a small system.